SCHEMBL1471333

SCHEMBL1471333

CS(=O)(=O)Nc1ccccc1NCCNCc1cccc(C(=O)N2CCCCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.49
PKM P14618 1/20 0.49
NPC1 O15118 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.43
TP53 P04637 2/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
CNR2 P34972 1/20 0.43
RECQL P46063 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8305984 0.88 RAB9A (0.53) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1470886 0.87 RAB9A (0.45) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL14382950 0.87 HPGD (0.49) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1470949 0.85 RAB9A (0.47) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL14281309 0.85 RAB9A (0.47) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1470779 0.85 RAB9A (0.47) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1471258 0.85 RAB9A (0.47) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1471433 0.85 HPGD (0.47) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1471308 0.84 HPGD (0.53) RAB9APKMNPC1SMN1; SMN2ALDH1A1
SCHEMBL1471240 0.84 RAB9A (0.47) RAB9APKMNPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US claimed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US claimed
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
WO-2005021525-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-10 WO disclosed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 RAB9A 3100/4885PKM 1881/4885NPC1 514/4885
US-20050049239-A1 Aryl piperidine amides BDNF, NTRK2, OPRL1 RAB9A 3100/4885PKM 1881/4885NPC1 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.